CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 13.17: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.41%
Annual Rate
CNY 0.14Paid annual
Payout Ratio
87.3%High
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.55BCNY379.23M · vs all stocks (USD)
Trailing P/E
100.77xRevenue (TTM)
238.55MCNY35.43M · vs all stocks (USD)
Profit Margin
9.55%Beta
0.4710xvs all stocks
52-Week Change
5.66%vs all stocks
Market Capitalization
2.55BCNY379.23M · vs all stocks (USD)
Enterprise Value
2.13BCNY316.30M · vs all stocks (USD)
Trailing P/E
100.77xPrice to Sales (TTM)
9.69xPrice to Book (MRQ)
2.59xEnterprise to Revenue
8.93xEnterprise to EBITDA
38.24xGross Margin
72.93%Profit Margin
9.55%Operating Margin
17.36%Return on Assets (TTM)
1.04%Return on Equity (TTM)
2.24%Revenue (TTM)
238.55MCNY35.43M · vs all stocks (USD)
Revenue per Share (TTM)
3.12CNYUpdated Aug 20, 2026Quarterly Revenue Growth
7.10%Gross Profit (TTM)
178.67MCNY26.54M · vs all stocks (USD)
EBITDA (TTM)
56.78MCNY8.43M · vs all stocks (USD)
Net Income (TTM)
22.79MCNY3.38M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
10.70%Operating Cash Flow (TTM)
50.44MCNY7.49M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-25.79MCNY-3.83M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1450CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.41%vs all stocks
Payout Ratio
87.25%Minority Interest (Equity)
30.51MCNYFY2025 · Dec 31, 2025Revenue
234.84MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
55.74MCNYFY2025 · Dec 31, 2025Gross Profit
179.10MCNYFY2025 · Dec 31, 2025Operating Income
17.14MCNY2.55M · vs all stocks (USD)
Pre-tax Income
21.00MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.10MCNYFY2025 · Dec 31, 2025Net Income
19.90MCNYFY2025 · Dec 31, 2025EBIT
21.44MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
56.78MCNYFY2025 · Dec 31, 2025Research & Development
11.25MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
109.49MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.54MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
450.02KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
444.83KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2863CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2863CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
76.49MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
76.49MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
19.90MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.00MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
18.24MCNYFY2025 · Dec 31, 2025Free Cash Flow
-47.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
28.95MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
19.90MCNYFY2025 · Dec 31, 2025Other Non-cash Items
523.00KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.25MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.43MCNYFY2025 · Dec 31, 2025Capital Expenditures
-66.06MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.08BCNYFY2025 · Dec 31, 2025Sale of Investments
956.78MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-185.64MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
11.53MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-10.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.32MCNYFY2025 · Dec 31, 2025Other Financing Charges
-5.36MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-24.15MCNYFY2025 · Dec 31, 2025Shares Outstanding
76.49MSharesUpdated Aug 20, 2026Float Shares
40.43MSharesUpdated Aug 20, 2026% Held by Insiders
50.58%vs all stocks
% Held by Institutions
7.14%vs all stocks
Total Cash (MRQ)
222.05MCNY32.98M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.94CNYUpdated Aug 20, 2026Total Debt (MRQ)
39.59MCNY5.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0434xCurrent Ratio (MRQ)
4.73xBook Value per Share (MRQ)
11.69CNYUpdated Aug 20, 2026Total Assets
1.06BCNY157.67M · vs all stocks (USD)
Total Current Assets
342.86MCNYFY2025 · Dec 31, 2025Total Liabilities
126.80MCNYFY2025 · Dec 31, 2025Total Non-current Assets
718.72MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.38MCNYFY2025 · Dec 31, 2025Total Current Liabilities
88.42MCNYFY2025 · Dec 31, 2025Cash
28.94MCNYFY2025 · Dec 31, 2025Cash Equivalents
565.59KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
29.51MCNYFY2025 · Dec 31, 2025Other Short-term Investments
206.95MCNYFY2025 · Dec 31, 2025Accounts Receivable
32.92MCNYFY2025 · Dec 31, 2025Inventory
28.19MCNYFY2025 · Dec 31, 2025Accounts Payable
48.84MCNYFY2025 · Dec 31, 2025Short-term Debt
11.61MCNYFY2025 · Dec 31, 2025Other Current Liabilities
390.75KCNYFY2025 · Dec 31, 2025Common Stock (Book)
76.49MCNYFY2025 · Dec 31, 2025Retained Earnings
391.07MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
934.78MCNY138.83M · vs all stocks (USD)
52-Week Low
21.88CNYUpdated Aug 20, 202652-Week High
39.98CNYUpdated Aug 20, 202652-Week Change
5.66%vs all stocks
Beta
0.4710xvs all stocks
50-Day MA
24.95CNYUpdated Aug 20, 2026200-Day MA
29.34CNYUpdated Aug 20, 2026Avg 10-Day Volume
3.44MSharesUpdated Aug 20, 2026Avg 30-Day Volume
2.13MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.3000CNYUpdated Aug 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.17: safe zoneNotable
Altman Z-Score: 13.17
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule